INFLUENCE OF LOW DOSE OESTROGEN ON CIRCULATING PROLACTIN, LH AND FSH LEVELS IN POST-MENOPAUSAL WOMEN

1976 ◽  
Vol 83 (1) ◽  
pp. 9-14 ◽  
Author(s):  
C. Robyn ◽  
M. Vekemans
Keyword(s):  
Breast Cancer ◽  
Treatment Period ◽  
Prolactin Level ◽  
Low Dose ◽  
Serum Prolactin ◽  
Blood Samples ◽  
Menopausal Women ◽  
Pre Treatment ◽  
Post Menopausal

ABSTRACT The effect on serum prolactin, LH and FSH levels of 25 μg ethinyloestradiol administered daily per os during 27 consecutive days was investigated in 5 post-menopausal women aged 52-78. Blood samples were collected before, during and after treatment. The hormones were assayed in serum by radioimmunological methods. Both LH and FSH decreased progressively and significantly from 120 and 115 mIU/ml before treatment to 52 and 51 mIU/ml, respectively after three weeks of oestrogen administration. Two weeks after interruption of treatment, LH (90 mIU/ml) and FSH (112 mIU/ml) were significantly higher than during the last week of treatment. Mean prolactin level increased from 127 μU/ml before treatment to 237 μU/ml after 10 days of oestrogen administration (P < 0.001). This increase was significant after 4 to 8 days and the levels remained about twice as high as the control values for the rest of the treatment period. Two weeks after interruption of treatment, serum prolactin had fallen (136 μU/ml) to the pre-treatment levels. Such results raise the question of possible effects of elevated levels of this hormone during long term oestrogen medication in post-menopausal women on the development of breast cancer.

HORMONE THERAPY IN METASTATIC BREAST CANCER: CLINICAL RESPONSE AND URINARY GONADOTROPHINS

1965 ◽  
Vol 50 (3) ◽  
pp. 345-356
Author(s):  
J. G. Stewart ◽  
L. G. Skinner ◽  
P. J. O'Connor
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Clinical Response ◽  
Metastatic Breast ◽  
Site Specificity ◽  
Metastatic Breast Carcinoma ◽  
Remission Period ◽  
Menopausal Women ◽  
Pre Treatment ◽  
Post Menopausal

ABSTRACT The total urinary gonadotrophin output of a group of post menopausal women with metastatic breast carcinoma undergoing hormone therapy, which in every case initially consisted of treatment with diethylstilboestrol, DES (ca. 20 mg/d), has been studied for periods varying from seven months to 3½ years. No correlation between gonadotrophin output and clinical response was found, except that in all cases showing objective regression urinary gonadotrophin remained low throughout the remission period. A low level of gonadotrophin output was not, however, necessarily indicative of a good clinical remission. Following withdrawal of DES, and independent of the period of therapy, recovery to pre-treatment levels was the rule rather than the exception. A small group of patients maintained on a lower dose of DES (3–5 mg/d) showed the same degree of suppression of urinary output as those receiving 20 mg/d, and several of these exhibited objective remissions. The study has emphasised the importance of site specificity in the response to hormone therapy, and underlines the difficulties of relating the clinical response of the patient as a whole to changes in hormonal environment.

Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17564-e17564
Author(s):  
Nathan William Dana Lamond ◽  
Chris Skedgel ◽  
Daniel Rayson ◽  
Tallal Younis
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Adverse Events ◽  
Economic Impacts ◽  
Endocrine Treatment ◽  
Model Parameters ◽  
Life Years ◽  
Menopausal Women ◽  
Post Menopausal

e17564 Background: Adjuvant zoledronic acid (ZA) appears to improve disease-free survival (DFS) in women with endocrine-sensitive breast cancer and low estrogen levels (LEL) including post-menopausal women, and pre-menopausal women treated with LHRH agonists. ZA, however, is also associated with potential adverse events and incremental drug acquisition costs. An overall assessment of the long-term clinical and economic impacts of adjuvant ZA may therefore help guide the decision to adopt this novel therapeutic option. We examined the incremental quality-adjusted life-years (QALY) and costs per QALY associated with adjuvant endocrine treatment plus ZA relative to endocrine treatment without ZA in women with endocrine-sensitive breast cancer and LEL. Methods: A generic state-transition model was developed to compute cumulative costs, from a Canadian perspective, and QALY associated with and without adjuvant ZA (4 mg IV qM*3→ q3M*8 → q6M*5) over a 25-year horizon for women with endocrine-sensitive breast cancer and LEL. Costs, utilities, DFS and adverse events were derived from relevant clinical trials, the literature and local resources. One-way and probabilistic sensitivity analyses were conducted for key model parameters. Results: Adjuvant ZA was associated with incremental QALY gains of 0.80 and 0.52 and resultant CU estimates of $3,571 and $7,683 per QALY gained in pre- and post-menopausal women, respectively. CU estimates were robust across reasonable uncertainty ranges in all parameters. Conclusions: Adjuvant ZA appears to be associated with long-term QALY gains in women with endocrine-sensitive breast cancer and LEL as well as CU estimates that are well below commonly accepted North American thresholds. The favourable long-term clinical and economic impacts observed in this study further support the use of adjuvant ZA in this setting.

scholarly journals 82P Risk factors for breast cancer: A case-control study among post-menopausal women in Pakistan

2016 ◽  
Vol 27 ◽  
pp. ix24
Author(s):  
N.A. Jadoon ◽  
M. Hussain ◽  
F.U. Sulehri ◽  
A. Zafar ◽  
A. Ijaz
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Case Control Study ◽  
Case Control ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Control Study

scholarly journals Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank

2021 ◽  
Author(s):  
Sandar Tin Tin ◽  
Gillian K. Reeves ◽  
Timothy J. Key
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Invasive Breast Cancer ◽  
Cox Regression ◽  
Menopausal Status ◽  
Endogenous Hormones ◽  
Uk Biobank ◽  
Menopausal Women ◽  
Post Menopausal

Abstract Background Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. Methods UK Biobank was used. Hormone concentrations were measured in serum collected in 2006–2010, and in a repeat subsample (N ~ 5000) in 2012–13. Incident cancers were identified through data linkage. Cox regression models were used, and hazard ratios (HRs) corrected for regression dilution bias. Results Among 30,565 pre-menopausal and 133,294 post-menopausal women, 527 and 2,997, respectively, were diagnosed with invasive breast cancer during a median follow-up of 7.1 years. Cancer risk was positively associated with testosterone in post-menopausal women (HR per 0.5 nmol/L increment: 1.18; 95% CI: 1.14, 1.23) but not in pre-menopausal women (pheterogeneity = 0.03), and with IGF-1 (insulin-like growth factor-1) (HR per 5 nmol/L increment: 1.18; 1.02, 1.35 (pre-menopausal) and 1.07; 1.01, 1.12 (post-menopausal); pheterogeneity = 0.2), and inversely associated with SHBG (sex hormone-binding globulin) (HR per 30 nmol/L increment: 0.96; 0.79, 1.15 (pre-menopausal) and 0.89; 0.84, 0.94 (post-menopausal); pheterogeneity = 0.4). Oestradiol, assessed only in pre-menopausal women, was not associated with risk, but there were study limitations for this hormone. Conclusions This study confirms associations of testosterone, IGF-1 and SHBG with breast cancer risk, with heterogeneity by menopausal status for testosterone.

scholarly journals Tamoxifen and oxidative stress: an overlooked connection

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nermin S. Ahmed ◽  
Marek Samec ◽  
Alena Liskova ◽  
Peter Kubatka ◽  
Luciano Saso
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Gold Standard ◽  
Pharmacological Activities ◽  
Standard Drug ◽  
Menopausal Women ◽  
Wide Range ◽  
Post Menopausal ◽  
Apoptotic Effects ◽  
And Oxidative Stress

AbstractTamoxifen is the gold standard drug for the treatment of breast cancer in pre and post-menopausal women. Its journey from a failing contraceptive to a blockbuster is an example of pharmaceutical innovation challenges. Tamoxifen has a wide range of pharmacological activities; a drug that was initially thought to work via a simple Estrogen receptor (ER) mechanism was proven to mediate its activity through several non-ER mechanisms. Here in we review the previous literature describing ER and non-ER targets of tamoxifen, we highlighted the overlooked connection between tamoxifen, tamoxifen apoptotic effects and oxidative stress.

Sign in / Sign up

Export Citation Format

Share Document